Activity Overview
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) impose substantial burdens at both the patient and societal level. Intravitreal anti-VEGF injections are the standard of care, but poor adherence and high treatment burden with earlier options have led to the development of newer agents with the potential for longer treatment intervals. In this first episode of a 6-part series, an expert faculty member shares insights into the use of these newer therapies for the management of patients with nAMD.
Target Audience
This educational curriculum is directed toward retina specialists and ophthalmologists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the rationale for durable, next-generation anti-VEGF therapy as a first-line or switch strategy in nAMD
- Apply a treat-and-extend algorithm incorporating OCT-based fluid assessment and interval adjustment criteria
- Identify patients with nAMD who are most likely to benefit from next-generation anti-VEGF based on clinical and anatomic characteristics
Anat Loewenstein, MD
Professor of Ophthalmology
Vice Dean Tel Aviv University
Disclosures: Advisor, Consultant, Fee for Service Recipient:4DMT, AbbVie, Astellas, Bayer, Boehringer Ingelheim, Eyepoint Ocular Therapeutix, Oculis, Revenio, Roche, Voiant. Ownership interests in publicly traded companies: Revenio. Ownership interests in privately held Companies: Notal Vision.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated
all conflicts of interest for faculty, staff, and planners prior to the start
of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This
activity may have used AI-assisted tools to support educational development.
All content was reviewed and approved by qualified faculty or planners. The
accredited provider retains full responsibility for accuracy, balance, and
independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here